{"name":"Claes-Göran Östenson","slug":"claes-g-ran-stenson","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ARA 290","genericName":"ARA 290","slug":"ara-290","indication":"Type 2 diabetes","status":"phase_2"}]}],"pipeline":[{"name":"ARA 290","genericName":"ARA 290","slug":"ara-290","phase":"phase_2","mechanism":"ARA 290 is a peptide that acts as a glucagon receptor antagonist.","indications":["Type 2 diabetes"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFB4TzVFbmNub0l4bF9DR1lFYVRlVThWeDR6YnQ4cVZnT0V5MTRadmd4NDdVZ1ZNUXNERnZ3Q0hQNGF2R29CR2lrejg0a3BWNnBSUE5oNlNablJoZ2pjZ0RB?oc=5","date":"2022-09-20","type":"pipeline","source":"Nature","summary":"Diabetes downregulates the antimicrobial peptide psoriasin and increases E. coli burden in the urinary bladder - Nature","headline":"Diabetes downregulates the antimicrobial peptide psoriasin and increases E. coli burden in the urinary bladder","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1Sa2dQeFh0WDVTSzZiSUV2TUtPeFZtemIzelJtb0w4c05XVWQwa2hsYTlxRlRBaDhFeGJ1QV9pdDBCX0w0cm9MOW9QaWItSVpkNnlMakoyOE9SekQ5U1hN?oc=5","date":"2019-01-24","type":"pipeline","source":"Nature","summary":"Profiling and activity screening of Dammarane-type triterpen saponins from Gynostemma pentaphyllum with glucose-dependent insulin secretory activity - Nature","headline":"Profiling and activity screening of Dammarane-type triterpen saponins from Gynostemma pentaphyllum with glucose-dependen","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}